Literature DB >> 26676384

Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection.

Alessandro Buda1, Andrea Lissoni2, Rodolfo Milani2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26676384      PMCID: PMC4695451          DOI: 10.3802/jgo.2016.27.e11

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


× No keyword cloud information.
To the editor: We read with great interest the article by Bogani et al. [1], highlighting some of the debated issues regarding the role of sentinel lymph node (SLN) mapping in endometrial cancer. However, taking a cue from this commentary and from the available evidence in the literature regarding the surgical staging of endometrial cancer, we would like to broaden the debate to include several important aspects not covered by the authors. First of all, the authors state that even if hysteroscopic injection represents a more demanding and less reproducible technique, it is the more reliable and effective approach in detecting the lymphatic drainage of a tumor, whereas cervical injection seems to be more effective in detecting the lymphatic drainage of the uterus. We disagree with that definition which sounds redundant and in contrast with the evidence the literature. In 1999, Linehan et al. [2] demonstrated that peritumoral intraparenchymatous SLN dye injection was not superior to intradermal dye injection in SLN detection of patients with breast cancer. In endometrial cancer patients one of the main criticisms regards cervical site injection and whether it map the organ rather than the tumor. In any case, the study of Khoury-Collado et al. [3] challenged the reservations about the effectiveness of cervical site injection, since after a cervical site injection, SLNs were three times more likely to harbor disease than non SLNs. More recently, Rossi et al. [4] confirmed that cervical injection of indocyanine green achieved a higher detection rate and a similar anatomic nodal distribution as hysteroscopic injection for SLN mapping in endometrial cancer patients. Furthermore, the rationale of using the cervix as injection site for SLN mapping has been confirmed by classic morphological studies. A well-known lymphatic pathway is composed of a complex network of bilaterally independent lymphatic channels, draining the uterine cervix and the corpus primarily from the lateral parametrial regions [5]. By applying the recently published SLN algorithm of the Memorial Sloan Kettering Cancer Center (MSKCC) [6] all the women with an apparently uterine-confined disease who undergo a cervical injection for mapping it is clearly stated that any suspicious nodes should be removed regardless of mapping. From our point of view, hysteroscopic tracer injection includes some critical drawbacks: (1) the necessity for a more demanding technique with a longer learning curve compared to the cervical injection, requires the support of nuclear medicine when Tc99m is injected with the patient still awake during the procedure; (2) if we can say that a tracer injection via hysteroscopy its preferable in the case of focal endometrial lesion, when the tumor fills the majority of the uterine cavity, it’s not easy to decide where to inject the dye in respect of the hypothesis that hysteroscopic injection “is effective in detecting lymphatic drainage of the tumor”; and (3) considering that the exclusive aortic migration can occur more frequently in the case of a fundal high grade tumor with a deep myometrial infiltration, is it really a commitment to standardize such a demanding technique for such a limited number of cases? From our preliminary experience in this subset of select cases, and based on preoperative histology, the application of an integrated positron emission tomography/computed tomography/SLN algorithm [7] achieved excellent results. This strategy allows for staging of all cases and provides useful individualized information that may be a guide in deciding further therapy. Furthermore, the incidence of para-aortic metastasis in the presence of negative bilateral pelvic nodes in surgically staged endometrial cancer patients is 1% to 3% [8]. Considering the published series including more than 100 cases of endometrial cancer patients (6,858 evaluated patients), the overall rate of isolated aortic metastasis recorded was 1.7% (Table 1) [91011121314151617181920212223]. Mariani et al. [24] already underlined the issue of a low incidence of isolated aortic metastasis in 2001 in a large series of endometrial cancer patients suggesting that the aortic involvement with a skipped pelvic route is probably a late and rare event.
Table 1

Rate of isolated aortic nodal metastasis with negative pelvic lymph nodes in patients with endometrial cancer (published series with at least 100 cases)

SourceYearIsolated aortic metastasis
Creasman et al. [9]*198712/563 (2.1)
Morrow et al. [10]*199118/802 (2.2)
Ayhan et al. [11]19956/209 (3.0)
Onda et al. [12]19972/173 (1.2)
Hirahatake et al. [13]19972/160 (1.3)
Mariani et al. [14]20045/229 (2.2)
Nomura et al. [15]20064/105 (3.8)
Tanaka et al. [16]20061/101 (1)
Mariani et al. [17]20089/265 (3.4)
Hoekstra et al. [18]20097/1,487 (0.5)
Lee et al. [19]20097/284 (2.5)
Fujimoto et al. [20]20097/313 (2.2)
Abu-Rustum et al. [7]200912/734 (1.6)
Chiang et al. [21]20112/156 (1.3)
Dogan et al. [22]20122/145 (1.4)
Milam et al. [23]*201212/532 (2.2)
Total108/6,258 (1.7)

Values are presented as number/total number (%).

*Gynecologic Oncology Group Study.

Sentinel node mapping represents an acceptable valid approach for surgical staging of patients with apparently confined early stage endometrial cancer with normal-appearing nodes. Therefore, in the case of suspicious preoperative imaging or intraoperative findings, the nodes should be evaluated/biopsied as part of an extent-of-disease evaluation, consequently overriding the importance of SLN mapping. By applying a well-defined algorithm, the MSKCC group achieved a very low false-negative rate—likely below 5% [6]. Moreover, the detection of stage IIIC disease is high, particularly in the pelvis. In absence of bilateral mapping a side-specific lymphadenectomy including the iliac and obturator nodes should be performed and this approach has been recently included in the National Comprehensive Cancer Network (NCCN) guidelines [25]. The detection of a stage IIIC2 disease may be higher if routine para-aortic lymphadenectomy is incorporated but the survival advantage of systematic aortic dissection in stage IIIC cases remains to be determined through a prospective trial not yet available. In our opinion, the cervical injection still remains the easiest and most reproducible way to perform SLN mapping but at the same time, hysteroscopy injection in well skilled hands represents a valid alternative.
  24 in total

1.  Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients.

Authors:  D C Linehan; A D Hill; T Akhurst; H Yeung; S D Yeh; K N Tran; P I Borgen; H S Cody
Journal:  Ann Surg Oncol       Date:  1999 Jul-Aug       Impact factor: 5.344

2.  Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer.

Authors:  A Mariani; M J Webb; G L Keeney; K C Podratz
Journal:  Gynecol Oncol       Date:  2001-04       Impact factor: 5.482

3.  Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer.

Authors:  H Nomura; D Aoki; N Suzuki; N Susumu; A Suzuki; Y Tamada; F Kataoka; A Higashiguchi; S Ezawa; S Nozawa
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

4.  A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma.

Authors:  K Hirahatake; H Hareyama; N Sakuragi; M Nishiya; S Makinoda; S Fujimoto
Journal:  J Surg Oncol       Date:  1997-06       Impact factor: 3.454

5.  Can we omit para-aorta lymph node dissection in endometrial cancer?

Authors:  Hidenori Tanaka; Hirokazu Sato; Hiroshi Miura; Naoki Sato; Toshio Fujimoto; Yoshitomo Konishi; Osamu Takahashi; Toshinobu Tanaka
Journal:  Jpn J Clin Oncol       Date:  2006-07-26       Impact factor: 3.019

6.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Authors:  W T Creasman; C P Morrow; B N Bundy; H D Homesley; J E Graham; P B Heller
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

7.  Tumor status of lymph nodes in early endometrial cancer in relation to lymph node size.

Authors:  A Ayhan; Z S Tuncer; R Tuncer; K Yüce; T Küçükali
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1995-05       Impact factor: 2.435

8.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

Authors:  C P Morrow; B N Bundy; R J Kurman; W T Creasman; P Heller; H D Homesley; J E Graham
Journal:  Gynecol Oncol       Date:  1991-01       Impact factor: 5.482

9.  Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy.

Authors:  T Onda; H Yoshikawa; K Mizutani; M Mishima; H Yokota; H Nagano; Y Ozaki; A Murakami; K Ueda; Y Taketani
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  A critical assessment on the role of sentinel node mapping in endometrial cancer.

Authors:  Giorgio Bogani; Antonino Ditto; Fabio Martinelli; Mauro Signorelli; Stefania Perotto; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2015-10-08       Impact factor: 4.401

View more
  1 in total

1.  Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer.

Authors:  Hans Nagar; Nina Wietek; Richard J Goodall; Will Hughes; Mia Schmidt-Hansen; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2021-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.